These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35344670)

  • 1. Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease.
    Maekawa M; Maekawa T; Sasase T; Takagi K; Takeuchi S; Kitamoto M; Nakagawa T; Toyoda K; Konishi N; Ohta T; Yamada T
    Physiol Res; 2022 Apr; 71(2):209-217. PubMed ID: 35344670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal transcriptome analysis of uninephrectomized db/db mice identified a mechanism for the transition to severe diabetic nephropathy.
    Maekawa M; Maekawa T; Sasase T; Wakashima T; Uemura A; Uno K; Ohta T; Yamada T
    Exp Anim; 2024 Feb; 73(1):29-40. PubMed ID: 37482420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.
    Østergaard MV; Secher T; Christensen M; Salinas CG; Roostalu U; Skytte JL; Rune I; Hansen HH; Jelsing J; Vrang N; Fink LN
    Am J Physiol Renal Physiol; 2021 Aug; 321(2):F149-F161. PubMed ID: 34180715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice.
    Reddy MA; Sumanth P; Lanting L; Yuan H; Wang M; Mar D; Alpers CE; Bomsztyk K; Natarajan R
    Kidney Int; 2014 Feb; 85(2):362-73. PubMed ID: 24088954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of salt supplementation in uninephrectomized KK-Ay mice: Examining the potential of a diabetic kidney disease model.
    Sano R; Ryu K; Sasase T; Shinozaki Y; Teoh SH; Yamaguchi A; Uno K; Maekawa T; Ohta T; Miyajima K
    J Toxicol Sci; 2023; 48(11):597-606. PubMed ID: 37914287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
    Tahara A; Takasu T
    Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.
    Harlan SM; Heinz-Taheny KM; Sullivan JM; Wei T; Baker HE; Jaqua DL; Qi Z; Cramer MS; Shiyanova TL; Breyer MD; Heuer JG
    J Am Soc Nephrol; 2018 Feb; 29(2):477-491. PubMed ID: 29061652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
    Deb DK; Sun T; Wong KE; Zhang Z; Ning G; Zhang Y; Kong J; Shi H; Chang A; Li YC
    Kidney Int; 2010 Jun; 77(11):1000-9. PubMed ID: 20182412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy.
    Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
    Am J Nephrol; 2006; 26(1):50-8. PubMed ID: 16508247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice.
    Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
    Nephron Exp Nephrol; 2007; 105(2):e45-52. PubMed ID: 17139189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
    Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H; Suzuki H
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):380-6. PubMed ID: 15076221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF; Lyle PA;
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
    Kakimoto T; Okada K; Hirohashi Y; Relator R; Kawai M; Iguchi T; Fujitaka K; Nishio M; Kato T; Fukunari A; Utsumi H
    J Endocrinol; 2014 Jul; 222(1):43-51. PubMed ID: 24781258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.